Transcriptome analysis of an AKT inhibitor-resistant endometrial cancer cell line-Reference-Cited by-同舟云学术

Transcriptome analysis of an AKT inhibitor-resistant endometrial cancer cell line

Published:2024-03-13 Issue:2 Volume:76 Page:379-389
ISSN:1734-1140
Container-title:Pharmacological Reports
language:en
Short-container-title:Pharmacol. Rep

Author:

Onishi Takafumi^ORCID,Takashima Tsuyoshi^ORCID,Shibahara Kazuki^ORCID,Takagi Shoji^ORCID,Tanaka Shinichi^ORCID,Mori Michihiro^ORCID,Odashima Hirokazu,Osawa Yukihiko,Hattori Manabu

Funder

Kyoto Tachibana university

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s43440-024-00581-w.pdf

Reference26 articles.

1. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer. 2016;26:2–30.

2. Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015;33:930–6.

3. Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22:138.

4. Pavlidou A, Vlahos NF. Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer. Sci World J. 2014;2014:709–36.

5. Peng Y, Wang Y, Zhou C, Mei W, Zeng C. PI3K/Akt/mTOR pathway and its role in cancer therapeutics: are we making headway? Front Oncol. 2022;12: 819128.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of prognostic biomarkers for endometrioid endometrial carcinoma based on the miRNA and mRNA co‐expression network regulated by estradiol;2024-07-15